Boehringer Ingelheim initiates real-world study of treatment sequencing in EGFR mutation-positive lung cancer

RIDGEFIELD, Conn., Dec. 12, 2017 /PRNewswire/ -- Boehringer Ingelheim has initiated GioTag, a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Data from approximately 190 patients who received tyrosine kinase inhibitors (TKI) ? afatinib in first-line, followed by second-line osimertinib as part of standard clinical practice ? will be analyzed to determine total time on treatment.    

Dr. Maximilian Hochmair, medical oncologist in Vienna and coordinating investigator in this trial, commented: "Around 50-60% of patients with NSCLC will develop a T790M resistance mutation following treatment with a first- or second-generation TKI. But with osimertinib, which specifically targets the T790M mutation, a second-line targeted treatment is now a realistic option, helping to delay the use of chemotherapy even further. With more targeted treatments available, it is becoming important for clinicians to understand how to optimally sequence treatments to ensure the best outcomes are achieved. This real-world study will generate important insights on resistance mutations and sequencing to further inform long-term treatment planning." 

The study, a retrospective review, will analyze data from 65 study centers in 11 countries to determine the time on treatment of afatinib as first-line therapy in EGFR mutation positive lung cancer followed by osimertinib for patients with T790M resistance mutation, in a real-world setting. Available data on mutations after treatment with osimertinib will also be collected. With limited information available on the results of sequential treatment with two targeted therapies, this study will provide insight into the impact of TKIs used in this patient population and subsequent chemotherapy treatment. The sequence of treatment with TKIs may be a key determinant of long-term patient outcomes in EGFR mutation positive NSCLC.

"This real-world study will help us evaluate the impact of multiple lines of targeted therapies and provide evidence to help inform treatment approaches to optimize outcomes for patients," said Thomas Lechner, Ph.D., Therapeutic Area Head Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.

Results from GioTag are expected to be available in 2018.

Afatinib is approved in the US under the brand name Gilotrif® and in a number of markets, including the EU, Japan, China, Taiwan and Canada under the brand name Giotrif® for use in patients with distinct types of EGFR mutation-positive NSCLC. Afatinib is also approved in the EU, US and other markets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed (on or) after treatment with platinum-based chemotherapy.

What is Gilotrif?

Gilotrif is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC):

• that has certain types of abnormal epidermal growth factor receptor (EGFR) genes. Your doctor will perform a test to check for certain types of abnormal EGFR genes, and make sure that Gilotrif is right for you. Gilotrif may be used when you have not had previous treatment for cancer that has spread to other parts of the body. It is not known if Gilotrif is safe and effective in treating lung cancer with other abnormal EGFR genes.

or

• that is squamous type and has spread to other parts of the body after you have tried chemotherapy that contains platinum.

It is not known if Gilotrif is safe and effective in children.

IMPORTANT SAFETY INFORMATION ABOUT Gilotrif

Before you take Gilotrif, tell your doctor if you:

• have kidney or liver problems
• have lung or breathing problems other than lung cancer
• have a history of severe dry eye or any other eye problems. Tell your doctor if you wear contact lenses.
• have heart problems
• have any other medical conditions
• are pregnant or plan to become pregnant. Gilotrif can harm your unborn baby. You should not become pregnant while taking Gilotrif.
• Women who are able to become pregnant should use effective birth control during treatment with Gilotrif and for at least 2 weeks after your last dose of Gilotrif. Talk to your doctor about birth control methods that may be right for you.
• Tell your doctor right away if you become pregnant or think you are pregnant while taking Gilotrif.
• are breastfeeding or plan to breastfeed. It is not known if Gilotrif passes into your breast milk. Do not breastfeed while taking Gilotrif and for 2 weeks after your last dose of Gilotrif. Talk to your doctor about the best way to feed your baby if you take Gilotrif.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Gilotrif may affect the way other medicines work, and other medicines may affect the way Gilotrif works.

What to avoid while taking Gilotrif

Limit your time in the sun. Gilotrif can make your skin sensitive to the sun. You could get or have worsening rash or acne. You could get a severe sunburn. Use sunscreen and wear a hat and clothes that cover your skin while you are taking Gilotrif if you have to be in sunlight.

Gilotrif may cause serious side effects, including:

• Diarrhea. Diarrhea is common with Gilotrif and may sometimes be severe. Severe diarrhea can cause loss of body fluid (dehydration) and kidney problems that can sometimes lead to death. During your treatment with Gilotrif, your doctor should prescribe medicines to treat diarrhea. Take this medicine exactly as your doctor tells you to. Tell your doctor if you have diarrhea. Get medical attention right away if your diarrhea does not go away or becomes severe.
• Skin reactions. Gilotrif can cause redness, rash, and acne. It is important to get treatment for skin reactions as soon as you notice them. Take medicines to help skin reactions exactly as your doctor tells you to. Get medical attention right away if you develop severe skin reactions such as peeling or blistering of the skin, or blisters in your mouth.
• Lung or breathing problems. Gilotrif may cause inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung problems, or any combination of the following symptoms: trouble breathing or shortness of breath, cough, or fever.
• Liver problems. Gilotrif can cause liver problems that can sometimes lead to death. Tell your doctor right away if you have any symptoms of a liver problem which may include:
• yellowing of your skin or the white part of your eyes (jaundice)
• dark or brown (tea-colored) urine
• pain on the upper right side of your stomach area (abdomen)
• bleeding or bruising more easily than normal
• feeling very tired

Your doctor will do blood tests to check your liver function during your treatment with Gilotrif.

• Eye problems. Tell your doctor right away if you have symptoms of eye problems. Symptoms may include:
• eye pain, swelling, redness, or tearing
• blurred vision
• sensitivity to light
• other changes in your vision
• Heart problems. Tell your doctor right away if you have any symptoms of a heart problem which may include:
• new or worsening shortness of breath while at rest or with activity
• cough
• tiredness
• swelling of your ankles, feet, or legs
• feeling that your heart is pounding or racing (palpitations)
• sudden weight gain

The most common side effects of Gilotrif include diarrhea, rash, mouth sores, nail inflammation, dry skin, acne, decreased appetite, nausea, vomiting, itching.

Gilotrif may cause decreased fertility in females and males. Talk to your doctor if you have concerns about your fertility.

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of Gilotrif. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088. 

Please see the full Prescribing Information, including Patient Information.

GF CONS ISI APRIL 2016

About Boehringer Ingelheim in Oncology
Boehringer Ingelheim's oncology research is driven by a passion to advance clinical practice and a determination to improve the lives of patients who are battling cancer. Through our own scientific innovation and partnerships, we are focused on discovering and providing novel best-in-class, breakthrough cancer medications that fit the needs of patients, caregivers and healthcare professionals. We have a clear strategy to become a leader in the field of lung cancer. Boehringer Ingelheim has successfully launched two products globally for NSCLC that have been widely adopted and established as valuable additions to current clinical practice. Continuous insights and learnings from research and development are key parts of innovation and our way forward to advance clinical practice in lung cancer and other cancer types.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 145 affiliates and about 50,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit our Corporate Social Responsibility Report.

In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.

For more information please visit https://www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS. 

Further Media Channels
www.facebook.com/BoehringerUS 
www.twitter.com/boehringerus 
www.youtube.com/user/BoehringerUS

SOURCE Boehringer Ingelheim Pharmaceuticals